fbpx Skip to main content

Working with CROs – From selection to managing relationships

When:

March 30, 2021 9:00 am – March 30, 2021 11:00 am PDT

Where:

Live Webinar

Biocom, Virtual Event

Registration Closed

There is an increasing trend in pharma/biotech industry to outsource studies to contract research organizations (CROs). There are over 3000 CROs globally that have a variable selection of models and services, which can make it difficult to decide who to partner with. This event discusses advantages and risks in using CROs and gives you tools for evaluating, selecting and managing CRO relationships.

Featured Speaker: Tiina Kähkönen, Chief Scientific Officer, OncoBone Ltd

Presentation Topic: How to choose the right CRO

Tiina Kähkönen 08-2020.jpg

Tiina Kähkönen did her MSc in a Drug Development and Pharmacology program, and her PhD focusing on drug research for breast cancer and especially for cancer-induced bone metastasis. She worked previously in a preclinical CRO offering efficacy models for oncology and skeletal diseases, first as a Research Director and later as Chief Scientific Officer. At OncoBone she serves clients as scientific advisor, where one of her duties includes assisting pharma and biotech clients in finding suitable vendors, such as CROs, for outsourcing preclinical studies.


Featured Speaker: Joe Flynn, Chief Commercial Officer, Inotiv

Presentation Topic: How to create value for clients above the value of the project

Joe Flynn.jpg

Joe Flynn joined Inotiv in July 2018, having served as chief commercial officer and executive vice president of Seventh Wave Laboratories. Appointed to his current role as chief commercial officer in February 2019, he is responsible for leading sales, marketing, client experience and program management efforts across Inotiv’s five sites.

Flynn has had an esteemed career as a senior executive in contract research, with over 25 years of strategic and operational experience focusing on pharmaceutical research and development. Prior to his tenure at Seventh Wave, Flynn was a global vice president of sales and client services for multiple divisions of Covance Laboratories. Prior to Covance, he held operational roles at PPD Inc. and ABC Laboratories (now Eurofins). Flynn is also a board member of the Missouri Biotechnology Association.


Featured speaker: Dinah Misner, Senior Director, Aligos Therapeutics

Presentation topic: Creating Successful Partnerships with CROs: From Quote Generation to Study Finalization and Beyond

Dinah Misner.jpg

Dinah has been in the pharmaceutical industry for over 20 years. She led the safety pharmacology and investigative toxicology labs at Roche Palo Alto (until 2010), and also participated on both discovery and development project teams where she was responsible for defining and leading preclinical safety assessment strategies. She then joined Celgene, where she headed the in vivo toxicology testing group overseeing the design and conduct of general toxicology and safety pharmacology studies and served as a project representative for discovery and investigative teams from 2010-2012. From 2012 to 2016, she was the Group Leader of the investigative toxicology group at Genentech, where she oversaw in vitro/ex vivo toxicology studies as well as mechanism of toxicity studies supporting Genentech’s small molecule and biotherapeutic discovery and development programs. At Genentech, she was also a project toxicologist representative for small molecule programs. She is currently a senior director at Aligos Therapeutics, where she is a toxicology project team representative on both discovery and development teams and is responsible for the design and conduct of in vitro and in vivo toxicology and safety pharmacology studies for treatment of liver diseases, encompassing small molecules as well as oligonucleotides.

Dinah received her PhD in Biomedical Sciences and was originally trained as an electrophysiologist in neuroscience at UCSD and was a post-doc at the Salk Institute. She is a board-certified toxicologist and safety pharmacologist, and is currently the pastpresident of the drug discovery toxicology specialty section and past president of NorCal SOT, and VP of the cardiovascular toxicology specialty section.


Join Zoom Meeting

https://biocom-org.zoom.us/j/95523628884?pwd=WFBnYlBWeXJlbytpSWozVGdIVExVZz09

Meeting ID: 955 2362 8884

Passcode: miSs9ej1

One tap mobile

+16699006833,,95523628884#,,,,*43075236# US (San Jose)

+12532158782,,95523628884#,,,,*43075236# US (Tacoma)

Dial by your location

+1 669 900 6833 US (San Jose)

+1 253 215 8782 US (Tacoma)

+1 346 248 7799 US (Houston)

+1 301 715 8592 US (Washington DC)

+1 312 626 6799 US (Chicago)

+1 929 436 2866 US (New York)

Meeting ID: 955 2362 8884

Passcode: 43075236

Find your local number: https://biocom-org.zoom.us/u/adlbG0yFEr


Price of Admission

Member

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2021-03-30

0

Refund before

Refund Before

Non-Member

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2021-03-30

0

Refund before

Refund Before

Registration Closed